The story of Viagra, formerly marketed by copyright, presents a intricate case study for investors considering the drug landscape . Despite its initial success and generation of billions in revenue , the intellectual property lapse has opened the door for alternative medications, greatly reducing earnings opportunities. This transition raises doubt